QNASL Drug Patent Profile

Which patents cover Qnasl, and what generic alternatives are available?

Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has forty-seven patent family members in twenty-nine countries.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qnasl

A generic version of QNASL was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QNASL

International Patents:	47
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,740
Drug Prices:	Drug price information for QNASL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QNASL
What excipients (inactive ingredients) are in QNASL?	QNASL excipients list
DailyMed Link:	QNASL at DailyMed

See drug prices for QNASL

Pharmacology for QNASL

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for QNASL

QNASL is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014		RX	Yes	No	10,188,811		Y
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012		RX	Yes	Yes	10,188,811		Y

Expired US Patents for QNASL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014	5,776,432
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,683,677
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,605,674
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,776,432

International Patents for QNASL

When does loss-of-exclusivity occur for QNASL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QNASL around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011316124
Brazil	112013008824
Canada	2814212
Chile	2013000958
China	103282070

Last updated: July 26, 2026

QNASL market dynamics and financial trajectory (sales drivers, price pressure, and generic/biosimilar risk)

QNASL (beclomethasone dipropionate) nasal aerosol is a branded intranasal corticosteroid with modest market share in US allergy rhinitis. Its commercial trajectory is shaped by (1) steady baseline demand from seasonal and perennial allergic rhinitis, (2) ongoing competitive price pressure from other branded and OTC intranasal steroids, and (3) loss of patent-protected exclusivity impact that shifts value toward line extensions and contract pricing. As of the latest publicly reported period, QNASL’s revenue profile is consistent with an “older specialty” branded product: low-to-mid single digit annual growth in some periods, otherwise flat-to-declining under channel normalization and payer-led substitution.

What is QNASL’s current market position for allergic rhinitis in the US?

QNASL is an intranasal corticosteroid indicated for allergic rhinitis (seasonal and perennial). The commercial market is crowded by both prescription and OTC nasal steroid products, which limits pricing power and drives frequent formulary placement reviews.

QNASL competitive set that affects market share

Key substitution pressures come from:

• Other prescription intranasal corticosteroids (examples include fluticasone furoate, fluticasone propionate, mometasone, budesonide products depending on specific brand/formulation and payer coverage).
• OTC alternatives in the US, especially intranasal fluticasone and other OTC nasal steroid options by class.

How payers manage QNASL

Payers typically steer within-class using:

• step therapy and preferred drug lists among nasal steroids
• formulary tier placement (often tier-2/tier-3 placement for branded options)
• quantity limits during peak allergy seasons

Market implication: QNASL tends to perform best where brand retention is protected by contracts, where QNASL is preferred on specific formularies, or where prescribers prefer its delivery device and dosing regimen.

What are QNASL’s key revenue drivers and volume assumptions?

QNASL’s financial trajectory is typically driven by a small set of levers:

• Seasonal demand: QNASL demand rises during spring and early fall allergy seasons, then normalizes.
• Formulary coverage: revenue is sensitive to placement on preferred lists.
• Adherence and device usability: intranasal therapies suffer adherence losses when patients do not use correctly or discontinue due to taste, odor, or irritation.
• Channel mix: pharmacy benefit versus cash/other channels materially changes net sales via discounting.

Evidence pattern seen in intranasal steroid brands

For products like QNASL, net sales often track:

• prescription volume changes driven by formulary and substitution
• net price changes driven by rebate and contract intensity
• mix changes as payers steer patients to the lowest cost in-class option

When does QNASL face major exclusivity cliffs for US competition and generic entry?

QNASL is an older active ingredient in a common therapeutic class. The most consequential exclusivity cliffs are:

• expiration of primary patents tied to the product in the US, and
• any remaining patent coverage tied to specific formulations, device aspects, or method-of-use.

Practical impact: once the core IP moat is gone, the market typically shifts quickly toward generics and lower-priced therapeutics through formulary changes. Even where a generic is available, brand retention can persist for a period due to inertia and prescriber familiarity, but payer coverage usually accelerates switching.

How to think about exclusivity timing in this class

In intranasal corticosteroids, post-expiration outcomes often follow a predictable path:

1. generic launches (or AB-rated lower-cost competitors) begin
2. payers update preferred drug lists
3. branded net pricing compresses through rebate pressure
4. market share shifts to the lowest cost option

Financial impact: even without immediate volume collapse, net pricing usually declines, translating into flat-to-down revenue.

What patents protect QNASL in the US, and how strong is the patent estate?

A full patent estate mapping requires Orange Book listings and litigation/patent publication review for QNASL’s exact NDA and strengths. That determination is not possible from the information available in this prompt.

Commercial implication (class-level): for established intranasal corticosteroids, once principal patents expire, the remaining estate often narrows to:

• formulation-specific patents
• method-of-use or dosing regimen patents
• device and spray-characteristics patents

If those remaining patents are weak or easily designed around, generic entry risk rises quickly.

What is the Orange Book status of QNASL and what generic entry risks exist?

Orange Book status requires an NDA-level pull of all listed patents and their expiration dates, along with any AB-rated generics. This cannot be completed from the information in this prompt.

What matters for business planning: the biggest generic entry risks are:

• loss of composition-of-matter coverage
• expiration of key formulation/suspension characteristics patents
• any still-pending patents that block product-specific entry

How does QNASL compare with Flonase and other intranasal steroids on pricing power and payer preference?

QNASL competes in a class where payer preference is typically price-led once multiple intranasal steroid options exist. OTC options increase pressure on branded nasal steroid pricing.

Key differentiators payers evaluate

• formulary tier and prior authorization requirements
• device and dosing convenience (patient persistence can matter)
• per-script cost at preferred tier versus non-preferred tier

Financial impact: QNASL can hold value where payers use a restricted set of preferred nasal steroids, where QNASL has negotiated contracts, or where specific patient populations respond better.

What patent litigation or Paragraph IV challenges affect QNASL?

Paragraph IV challenges require recorded filings tied to the relevant Orange Book patents and NDA. This cannot be determined from the information in this prompt.

Business implication: in intranasal corticosteroids, litigation outcomes often resolve quickly into settlement-based switching schedules. Where settlements occur, branded products can experience predictable step-downs in revenue after the first generic entry date covered by the settlement.

What is the financial trajectory for QNASL (net sales trend and drivers)?

QNASL’s financial trajectory in practice aligns with mature branded generics-in-class dynamics:

• initial years benefit from exclusivity and formulary penetration
• later years face rebate escalation and share loss to lower-priced competitors
• net sales trend often becomes flat-to-declining unless the brand gains new formulary wins, launches line extensions, or benefits from contracted pricing

Primary driver of changes year to year: net price versus volume.

• If volume declines modestly but net price remains stable, revenue can appear steady.
• If volume holds but net price compresses, revenue declines.
• If both volume and net price compress, revenue drops faster.

How do contract pricing and rebate intensity influence QNASL’s net sales?

For branded respiratory and allergy products, net sales are extremely sensitive to:

• rebate intensity
• wholesaler chargebacks
• payer-specific discounting and PBM formulary rebates

Typical commercial pattern after increased generic competition

When generics or lower cost alternatives expand:

• gross-to-net spreads rise (higher rebates/discounts)
• average net price falls
• the brand sustains a smaller residual share longer than implied by list price

What commercial risks exist for QNASL from generics, substitution, and OTC switching?

Three risk channels usually dominate:

1. In-class substitution: payers switch within intranasal corticosteroids at renewal.
2. OTC shift: if an OTC intranasal steroid is available and preferred, payer coverage pressure intensifies.
3. Patient behavior: patients may remain on a product initially even after coverage changes, but long-term persistence is limited when cheaper options are accessible.

Financial impact: even if prescription counts do not collapse immediately, net pricing typically declines first.

What manufacturing or delivery-device issues can affect QNASL performance?

Intranasal therapies can see revenue effects from:

• device supply constraints
• quality/regulatory production constraints
• packaging lot issues that interrupt fulfillment

Absent verified supply interruptions tied to QNASL in public filings, the dominant issue is usually market access, not manufacturing.

Key Takeaways

• QNASL’s market dynamics are dominated by mature class competition in allergic rhinitis and payer-led substitution.
• The commercial trajectory is typically governed more by net price compression and rebate intensity than by growth drivers.
• Major revenue inflection points come from loss of remaining patent protections tied to the exact NDA/strength and from subsequent generic launches and formulary updates.
• Without Orange Book-level patent and regulatory entry mapping, the precise exclusivity and litigation timeline cannot be verified here; business planning should treat QNASL as a brand exposed to step-down revenue risk in the post-exclusivity window.

FAQs

1) What payer categories usually determine QNASL coverage for allergic rhinitis?

Commercial formularies and PBM tiering decisions determine whether QNASL is preferred, non-preferred, or requires prior authorization.

2) Does OTC intranasal steroid access reduce QNASL prescription demand?

OTC availability in the class can reduce payer-covered demand and intensify branded net price pressure even when patients do not switch immediately.

3) What typically happens to branded intranasal steroid net sales after generic entry?

Net price usually falls first due to rebate pressure; then market share shifts as formularies update and prescribers and patients follow coverage incentives.

4) Are QNASL revenues more sensitive to volume or net price?

In mature branded intranasal products, net price is usually the faster-moving lever due to contract and rebate changes after competitor entry.

5) What factors influence persistence/adherence with QNASL?

Device usability, correct technique, and tolerability (irritation and local side effects) affect persistence and sustained prescription refill patterns.

---

References

No sources were provided in the prompt, and no NDA/Orange Book, financial filing, or litigation records are included here.

DrugChatter Q&A for QNASL

Why is qnasl so expensive?
Does medicare cover qnasl?